The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Mucopolysaccharidosis Treatment Market Expected To Change From 2026 To 2030?
The mucopolysaccharidosis treatment market has experienced significant expansion in recent years. It is anticipated to increase from $2.58 billion in 2025 to $2.78 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.7%. The growth observed in the historic period is attributed to factors including limited awareness of mps disorders, high treatment costs, slow adoption of enzyme therapy, restricted clinical trial availability, and a reliance on international drug supply.
The mucopolysaccharidosis treatment market is projected to experience robust expansion over the coming years. This market is anticipated to reach a valuation of $3.79 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.0%. Factors contributing to this growth during the forecast period include the broadening of gene therapy research, escalating investments in healthcare, enhancements in rare disease screening initiatives, expanded reimbursement options, and the development of precision medicine platforms. Key trends anticipated for the forecast period encompass progress in enzyme replacement therapy, the rising acceptance of stem cell transplantation, an increase in gene therapy development strategies, a heightened emphasis on early diagnosis and newborn screening, and the proliferation of specialized treatment facilities.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11942&type=smp
What Major Factors Are Driving The Mucopolysaccharidosis Treatment Market Forward?
The rising occurrence of different types of mucopolysaccharidosis is projected to fuel the expansion of the mucopolysaccharidosis treatment market in the coming years. Mucopolysaccharide, a complex carbohydrate, accumulates in the body’s tissues when an affected individual lacks the specific enzyme necessary for its breakdown. Treatments for Mucopolysaccharidosis (MPS) aim to hinder disease progression by reducing glycosaminoglycan (GAG) formation, managing symptoms, and averting complications via diverse therapeutic strategies. For instance, in July 2024, the Orphanet Journal of Rare Diseases, a France-based peer-reviewed open-access medical journal, reported that the incidence of mucopolysaccharidosis IVa (MPS IVa) is approximately 1 in 201,000 live births, although this number is believed to differ significantly across various populations. Likewise, the birth prevalence of Mucopolysaccharidosis VI (MPS VI) is estimated to fall within the range of 1 in 43,261 to 1 in 1,505,160, contingent on the specific population. Consequently, the growing prevalence of various forms of mucopolysaccharidosis will propel the mucopolysaccharidosis treatment market.
Which Segment Types Are Examined In The Mucopolysaccharidosis Treatment Market Segment Study?
The mucopolysaccharidosis treatment market covered in this report is segmented –
1) By Treatment: Enzyme Replacement Therapy, Stem Cell Therapy
2) By Disease: Mucopolysaccharidosis- I, Mucopolysaccharidosis- II, Mucopolysaccharidosis-IV, Mucopolysaccharidosis-VI, Other Diseases
3) By Route Of Administration: Intravenous, Intracerebroventricular
4) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Enzyme Replacement Therapy: Idursulfase (Elaprase), Laronidase (Aldurazyme), Velaglucerase Alfa (Vpriv), Galsulfase (Naglazyme)
2) By Stem Cell Therapy: Hematopoietic Stem Cell Transplantation (HSCT), Umbilical Cord Blood Transplantation, Gene Therapy Approaches
Which Trends Are Impacting The Progress Of The Mucopolysaccharidosis Treatment Market?
Leading companies in the MPS II treatment market are prioritizing the creation of advanced products, such as AAV gene therapies, to tackle the fundamental genetic causes of the disorder and achieve enduring neurological improvement. An AAV gene therapy is a precise genetic intervention that utilizes adeno-associated viral vectors to introduce functional genes into central nervous system cells, allowing for the sustained production of absent or insufficient proteins. For instance, in August 2025, REGENXBIO Inc., a US-based biotechnology firm, announced that the United States Food and Drug Administration extended its review period for RGX-121. This extension followed the submission of additional long-term clinical data from all key study participants, which aligned with earlier biomarker and neurodevelopmental findings. Favorable pre-license inspections and no safety concerns observed suggest continued regulatory momentum, strengthening the therapy’s promise to be the initial one-time treatment addressing the neurological manifestations of MPS II.
Which Players Are Part Of The Competitive Landscape Of The Mucopolysaccharidosis Treatment Market?
Major companies operating in the mucopolysaccharidosis treatment market are BioMarin Pharmaceuticals Inc., Sanofi S.A., Takeda Pharmaceutical Co. Ltd., JCR Pharmaceuticals Co. Ltd., Ultragenyx Pharmaceutical Inc., RegenxBio Inc., Sangamo Therapeutics Inc., Audentes Therapeutics Inc., Abeona Therapeutics Inc., Immusoft Corporation, Neurogene Inc., Mallinckrodt Pharmaceuticals, Green Cross Corporation, Denali Therapeutics Inc., Passage Bio Inc., Homology Medicines Inc., AVROBIO Inc., Rocket Pharmaceuticals Inc., Taysha Gene Therapies Inc., Freeline Therapeutics Holdings plc, 4D Molecular Therapeutics Inc., Sio Gene Therapies Inc., SpliceBio S.L., LogicBio Therapeutics Inc., Orchard Therapeutics plc, Asklepios BioPharmaceutical Inc.
Get The Full Mucopolysaccharidosis Treatment Market Report:
Which Region Leads The Mucopolysaccharidosis Treatment Market In Terms Of Market Share?
North America was the largest region in the mucopolysaccharidosis treatment market in 2025. The regions covered in the mucopolysaccharidosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Mucopolysaccharidosis Treatment Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Mucopolysaccharidosis Treatment Market 2026, By The Business Research Company
Contrast Media Market Report 2026
https://www.thebusinessresearchcompany.com/report/contrast-media-global-market-report
Medical Imaging Market Report
https://www.thebusinessresearchcompany.com/report/medical-imaging-global-market-report
Portable Magnetic Resonance Imaging Mri Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model